The Tortoise and the Hare: Wellpoint Slowly Gains on Part D Leaders
This article was originally published in RPM Report
Wellpoint is not one of the most aggressive players in the Medicare market, but it will be gaining the most new enrollees in 2008. Does slow and steady win this race?
You may also be interested in...
United, Humana and especially WellCare are taking their licks in the run-up to the third year of the Medicare prescription drug program. That is just the latest warning sign for pharma and biotech companies that a critical market is entering a critical turning point.
US FDA’s workshop to discuss new ideas to assess the impact of the opioid REMS comes after the industry collaboration behind the REMS has deemed the task essentially impossible.
Whether CME for pain management has the intended impact on prescribing is likely focus of new ‘suite of studies’ intended to assess the opioid REMS program. The challenges for FDA include teasing out the impact of the risk management program amid all the other public health efforts on opioids.